Capivasertib is an AKT inhibitor designed for the treatment of HR /HER2breast cancer, specifically targeting those with PIK3CA/AKT1/PTEN alterations. It works by keeping AKT signals from happening. There are two doses of the medicine: 200 mg and 400 mg tablets.
You should take 400 mg two times a day, for four days on, then three days off. Each bottle has 64 tablets.
Reviews
There are no reviews yet.